Dr. Kumar’s Take:
This was a randomized, double-blind, placebo-controlled trial of intravenous immunoglobulin (IVIG) in 35 children with PANDAS and moderate to severe OCD. During the six-week double-blind phase, the IVIG group’s OCD scores dropped more than the placebo group’s, but the difference was not statistically significant, and the trial failed to show IVIG was superior to placebo. Twenty-four of the 35 children were nonresponders at week 6 and went on to open-label IVIG. Across all participants, mean CY-BOCS improvement was 55% at week 12 and 62% at week 24, but open-label results carry no comparison group, so I read them cautiously. IVIG was safe and well tolerated. My honest read: this trial did not establish IVIG as an effective treatment for PANDAS, and the authors themselves call for larger trials that can identify biomarkers predicting who responds to immunotherapy.
Key Takeaways:
✔ IVIG was safe and well tolerated in children with PANDAS.
✔ In the double-blind phase, IVIG did not significantly outperform placebo.
✔ Responder rates were 35% with IVIG and 22% with placebo, and 24 of 35 children were nonresponders at week 6.
✔ Larger trials are needed to identify which children benefit from immunotherapy.
Actionable Tip:
If your child has sudden OCD symptoms following a strep infection, ask your doctor about PANDAS. Keep a symptom diary and track response to any treatments. Immune-based therapies remain unproven in controlled trials, so discuss them carefully with a clinician who treats PANDAS.
What Is This Study About?
This 6-week randomized, placebo-controlled trial studied 35 children who met criteria for PANDAS and moderate to severe OCD. PANDAS is hypothesized to occur when cross-reactive antibodies are produced in response to group A streptococcal infections. Researchers tested whether IVIG could reduce OCD symptoms.
Children received either IVIG at 1 g/kg/day on two consecutive days or placebo, with follow-up at 12 and 24 weeks. Those who did not respond in the double-blind phase were offered open-label IVIG at week 6.
Study Design:
- Participants: 35 children diagnosed with PANDAS and moderate to severe OCD
- Design: Randomized-entry, double-blind, placebo-controlled trial with optional open-label treatment for nonresponders
- Treatment: IVIG 1 g/kg/day for 2 days vs placebo
- Follow-up: 6, 12, and 24 weeks
- Main Measures:
- Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
- Clinical Global Impressions: Improvement (CGI-I)
- Responder Definition: ≥30% drop in CY-BOCS and a rating of “much” or “very much improved” on CGI-I
Results:
- Double-Blind Phase:
- IVIG group (n = 17) improved OCD scores by a mean of 24% ± 31%
- Placebo group (n = 18) improved by 12% ± 27%
- 6 responders in the IVIG group (35%) vs 4 in the placebo group (22%)
- The difference was not statistically significant
- Open-Label Phase:
- 24 participants met criteria for nonresponse and received open-label IVIG at week 6
- Among all participants, mean CY-BOCS improvement from baseline was 55% ± 33% at week 12
- Improvement was 62% ± 33% at week 24
How IVIG May Help in PANDAS
PANDAS is hypothesized to occur as a result of cross-reactive antibodies produced in response to group A streptococcal infections. IVIG is an immunomodulatory therapy, and earlier research had suggested it might lead to rapid and sustained symptom improvement in these children.
This trial did not support that. The double-blind comparison failed to demonstrate superiority of IVIG over placebo, and the between-group differences were smaller than the investigators anticipated. The improvements seen during open-label treatment came without a control group, so they cannot separate drug effect from the natural course of the illness. The authors argue that future trials need larger samples designed in part to identify biomarkers that predict a positive response to immunotherapy, and that the natural history of PANDAS itself deserves further study.
Related Studies and Research
This trial is part of a broader effort to understand autoimmune contributions to mental health in children.
Related Studies and Research
Tonsillectomy as a Treatment for PANDAS: Reviews the potential role of tonsil removal in reducing symptoms.
PANS Treatment: Large Survey Study: Examines treatment trends and outcomes in a large community-based sample.
PANDAS OCD Treatment Overview: Summarizes current treatment strategies for PANDAS-related OCD.
Podcast: Could Your Child’s Behavior Changes Be Cured with an Antibiotic?: A deep dive into the link between strep infections and dramatic neuropsychiatric symptoms.
Frequently Asked Questions
What is IVIG?
IVIG is an immunomodulatory therapy made from pooled antibodies. It is used to treat conditions thought to involve an abnormal immune response.
How long does IVIG take to work for PANDAS?
This trial cannot answer that. At the end of the 6-week double-blind phase, 24 of the 35 participants met criteria for nonresponse. Across all participants, mean CY-BOCS improvement was 55% at week 12 and 62% at week 24, but that period included open-label treatment with no comparison group.
Is IVIG safe for kids?
In this trial, IVIG was safe and well tolerated.
Should my child with PANDAS get IVIG?
This trial did not demonstrate that IVIG outperforms placebo, so I would not treat it as established therapy. Work with a clinician experienced in PANDAS, and understand that the evidence base here is still thin.
Conclusion
In this randomized, double-blind, placebo-controlled trial, IVIG did not outperform placebo for children with PANDAS and moderate to severe OCD. Responder rates were 35% with IVIG and 22% with placebo, a difference that was not statistically significant. IVIG was safe and well tolerated. Improvements recorded at 12 and 24 weeks came after open-label treatment without a control group, and the authors call for larger trials capable of identifying which children, if any, respond to immunotherapy.
